Chunling Li Selected Research

Aquaporins (Water Channels)

1/2021	Activation of TGR5 restores AQP2 expression via the HIF pathway in renal ischemia-reperfusion injury.
1/2020	Statins ameliorate cholesterol-induced inflammation and improve AQP2 expression by inhibiting NLRP3 activation in the kidney.
1/2019	Inhibition of IL-1β by Aliskiren Improved Renal AQP2 Expression and Urinary Concentration Defect in Ureteral Obstruction and Release.
4/2015	Aliskiren restores renal AQP2 expression during unilateral ureteral obstruction by inhibiting the inflammasome.
6/2008	Role of AQP1 in endotoxemia-induced acute kidney injury.
11/2006	Angiotensin II mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction.
2/2006	alpha-MSH prevents impairment in renal function and dysregulation of AQPs and Na-K-ATPase in rats with bilateral ureteral obstruction.
10/2005	Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism.
8/2005	COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction.
8/2004	EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chunling Li Research Topics

Disease

14	Ureteral Obstruction 01/2019 - 05/2003
12	Polyuria 01/2022 - 01/2002
10	Inflammation (Inflammations) 01/2021 - 01/2016
8	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 08/2004
7	Kidney Diseases (Kidney Disease) 01/2022 - 05/2015
7	Neoplasms (Cancer) 03/2020 - 09/2012
5	Rheumatoid Arthritis 01/2021 - 09/2017
5	Nephrogenic Diabetes Insipidus 01/2019 - 10/2016
4	Sepsis (Septicemia) 01/2022 - 10/2008
4	Wounds and Injuries (Trauma) 01/2022 - 08/2004
4	Ischemia 01/2021 - 08/2004
4	Infections 01/2021 - 03/2015
3	Hypoxia (Hypoxemia) 01/2021 - 12/2018
3	Hypertension (High Blood Pressure) 09/2020 - 07/2014
3	Body Weight (Weight, Body) 12/2019 - 10/2005
3	Diabetic Nephropathies (Diabetic Nephropathy) 01/2017 - 12/2014
3	Hypercalcemia (Milk Alkali Syndrome) 03/2004 - 01/2002
2	Fibrosis (Cirrhosis) 01/2022 - 10/2016
2	Obesity 01/2022 - 01/2021
2	Carcinoma (Carcinomatosis) 01/2022 - 07/2011
2	Osteoporosis 05/2021 - 01/2019
2	Dysbiosis 09/2020 - 07/2020
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020 - 07/2018
2	Experimental Arthritis 12/2019 - 09/2017
2	Arthritis (Polyarthritis) 12/2019 - 09/2017
2	Dehydration (Water Stress) 01/2019 - 10/2016
2	Acute Promyelocytic Leukemia 01/2019 - 08/2018
2	Necrosis 07/2018 - 07/2010
2	Hyperglycemia 12/2014 - 06/2006
2	Acidosis 12/2009 - 08/2008
2	Endotoxemia 10/2008 - 06/2008
1	Endometritis 03/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 03/2022
1	Chronic Renal Insufficiency 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Myopia 01/2022
1	Chronic Disease (Chronic Diseases) 05/2021
1	Bites and Stings (Sting) 01/2021

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2004
13	Aquaporins (Water Channels)IBA 01/2021 - 12/2002
7	SodiumIBA 06/2008 - 11/2003
6	Arsenic Trioxide (Trisenox)FDA Link 01/2021 - 09/2017
5	Aquaporin 2IBA 01/2021 - 05/2003
5	LithiumIBA 01/2019 - 10/2016
4	Renin InhibitorsIBA 01/2019 - 12/2014
4	InflammasomesIBA 01/2019 - 04/2015
4	aliskiren FDA Link 01/2019 - 12/2014
3	CalciumIBA 01/2022 - 03/2004
3	LipidsIBA 01/2022 - 12/2014
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2016
3	Small Interfering RNA (siRNA)IBA 01/2020 - 07/2011
3	Vitamin D FDA LinkGeneric 01/2019 - 01/2002
3	Hormones (Hormone)IBA 09/2012 - 02/2006
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 01/2020
2	CholesterolIBA 01/2022 - 01/2020
2	LipopolysaccharidesIBA 01/2022 - 06/2008
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 10/2008
2	Palmitic Acid (Hexadecanoic Acid)IBA 01/2021 - 07/2018
2	RNA (Ribonucleic Acid)IBA 01/2021 - 10/2016
2	Bile Acids and Salts (Bile Acids)IBA 01/2021 - 11/2018
2	Amino Acids FDA Link 01/2021 - 01/2020
2	SaltsIBA 09/2020 - 07/2020
2	FructoseIBA 09/2020 - 07/2020
2	Drinking WaterIBA 07/2020 - 06/2006
2	Biological ProductsIBA 01/2020 - 09/2013
2	Messenger RNA (mRNA)IBA 12/2019 - 01/2015
2	Eosine Yellowish-(YS) (Eosin)IBA 12/2019 - 07/2010
2	Hematoxylin (Haematoxylon)IBA 12/2019 - 07/2010
2	Pharmaceutical PreparationsIBA 01/2019 - 08/2018
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 07/2011
2	Tamoxifen FDA LinkGeneric 01/2019 - 09/2012
2	CreatinineIBA 01/2019 - 05/2015
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019 - 01/2016
2	Fibronectins (Fibronectin)IBA 07/2018 - 10/2016
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2017 - 05/2015
2	Sodium-Hydrogen ExchangersIBA 12/2009 - 06/2008
2	Adenosine Triphosphatases (ATPase)IBA 12/2009 - 02/2006
2	AcidsIBA 12/2009 - 08/2008
2	salicylhydroxamic acid (SHAM)IBA 12/2009 - 06/2004
2	alpha-MSHIBA 02/2006 - 08/2004
2	Urea (Carbamide)FDA LinkGeneric 10/2005 - 06/2004
2	Carrier Proteins (Binding Protein)IBA 08/2005 - 06/2004
1	16S Ribosomal RNAIBA 03/2022
1	ProteomeIBA 03/2022
1	Mitogen-Activated Protein KinasesIBA 03/2022
1	Long Noncoding RNAIBA 01/2022
1	Enhancer of Zeste Homolog 2 ProteinIBA 01/2022
1	TOR Serine-Threonine KinasesIBA 01/2022
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2022
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2022
1	RGFP966IBA 01/2022
1	IntegrinsIBA 01/2022
1	CationsIBA 01/2022
1	Blood Glucose (Blood Sugar)IBA 05/2021
1	Testosterone (Sustanon)FDA Link 05/2021
1	Protective AgentsIBA 05/2021

Therapy/Procedure

11	Therapeutics 01/2022 - 09/2012
1	Ligation 01/2022
1	Punctures 01/2022
1	Glycemic Control 05/2021